Increased telehealth adoption is boosting AI rare disease patient finder market growth
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Expected To Change From 2026 To 2030?
The artificial intelligence (AI)-driven rare disease patient finder market size has witnessed exponential growth in recent years. It is projected to expand from $1.62 billion in 2025 to $2.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 29.9%. The growth observed in previous periods is attributable to the increasing availability of electronic health records, the early adoption of data analytics in clinical research, the expansion of genomic databases, a rising focus on orphan diseases, and the initial use of AI in trial recruitment.
The market for artificial intelligence (AI)-driven rare disease patient finders is projected to experience rapid expansion in the coming years. This market is anticipated to reach $5.95 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 29.6%. This anticipated growth stems from several factors, including heightened investments in precision medicine research, an escalating need for quicker clinical trial enrollment, the broadening scope of real-world evidence analytics, increased partnerships between healthcare and life sciences companies, and stronger regulatory backing for rare disease advancements. Key trends predicted for this period involve a greater adoption of AI-based patient identification algorithms, an increasing integration of health data from multiple sources, enhanced automation in clinical trial recruitment processes, the proliferation of precision patient matching platforms, and a reinforced emphasis on facilitating rare disease research.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Primary Drivers Are Impacting The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Growth?
The future expansion of the artificial intelligence (AI)-driven rare disease patient finder market is anticipated, propelled by the growing adoption of digital health and telemedicine. Digital health encompasses the application of technology, software, and electronic instruments for monitoring, managing, and enhancing health and well-being. Telemedicine involves providing healthcare services remotely via telecommunications technology, including video consultations, mobile applications, and online platforms. This rising acceptance of digital health and telemedicine stems from both patients and providers seeking healthcare solutions that are convenient, save time, and are easily accessible. The artificial intelligence (AI)-driven rare disease patient finder aids digital health and telemedicine through precise patient identification, facilitation of remote monitoring, prompt virtual consultations, and customized care. For example, in November 2025, the Organisation for Economic Co operation and Development, an intergovernmental organization headquartered in France, noted that OECD nations have advanced in broadening access to Electronic Health Records (EHRs). The average availability of online digital health services in 2024 reached 82%, marking an increase from 79% in 2023 across countries with comparable data. Consequently, the growing adoption of digital health and telemedicine is propelling the expansion of the artificial intelligence (AI)-driven rare disease patient finder market.
What Are The Key Segment Divisions In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Segment Structure?
The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –
1) By Component: Software, Services
2) By Deployment Mode: Cloud-Based, On-Premises
3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications
4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users
Subsegments:
1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System
2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades
Which Trends Are Shaping Growth In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?
Companies operating within the AI-driven rare disease patient finder market are primarily focused on advancing technological capabilities, such as precision patient recruitment solutions. This effort is designed to improve the accuracy, speed, and overall efficiency of pinpointing eligible patients for rare disease clinical trials, thereby reducing recruitment timelines and elevating trial success rates. A precision patient recruitment solution represents a technology-driven methodology that utilizes advanced algorithms and real-world data to accurately identify and engage patients who fulfill specific clinical trial eligibility requirements. As an illustration, in April 2024, Citeline, a US-based business intelligence and data analytics company, introduced Citeline PatientMatch. This platform merges sophisticated algorithms with comprehensive real-world data, encompassing lab results, biomarkers, and electronic medical records from over 400 hospitals and health systems, to aid sponsors and investigators in efficiently finding eligible patients for clinical trials, streamlining the enrollment process, and supporting varied and intricate study protocols across multiple therapeutic areas.
Which Organizations Are Engaged In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?
Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.
Get The Full Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report:
Which Region Holds The Highest Market Share In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?
North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market 2026, By The Business Research Company
Artificial Intelligence In Cancer Diagnostics Market Report 2026
Ai In Medical Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report
Artificial Intelligence Ai In Clinical Trials Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
